ArticleFrontiers in endocrinology2024
Determining the status of small dense low-density lipoprotein cholesterol level in women undergoing menopausal transition.
Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Atherogenic Dyslipidemia and Its Association withInternational journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Research on small dense low-density lipoprotein cholesterol (sdLDL-C) and menopausal status remains scarce. Our aim is to evaluate the relationship between serum sdLDL-C level and different menopausal status in a Chinese women population. Methods: In 2022, a cross-sectional study was conducted including electronic standardized questionnaire surveys, anthropometric measurements, and biological specimen examinations based on communities. Permanent resident adults aged 30-69 years who lived in two communities in Zhejiang Province and participated in a community health examination from May 26 to September 17 were recruited. According to their menopausal status, the eligible women subjects were divided into premenopause, perimenopause, and postmenopause. Logistic regression model by SAS software was used to explore the association with sdLDL-C level and different menopausal status. Results: A total of 2,062 women subjects were included with a median age of 57 (51, 63) years. There were 451 (21.9%) premenopause, 87 (4.2%) perimenopause, and 1,524 (73.9%) postmenopause women. The median sdLDL-C level was 0.937 (0.685, 1.209) mmol/L, and the sdLDL-C levels showed a gradually and significantly upward trend in premenopause, perimenopause, and postmenopause women, and this peaked in the postmenopause women. Logistic regression analysis showed that after controlling the confounding factors, compared with premenopause, postmenopause was significantly associated with increased sdLDL-C concentration (OR = 1.514, 95% CI: 1.025-2.238), while no significant association was observed either between serum sdLDL-C and perimenopause (compared with premenopause) or between serum sdLDL-C and postmenopause (compared with perimenopause). Conclusions: An elevated sdLDL-C level was significantly associated with postmenopause and independent of chronological aging. The study supports that sdLDL-C is a promising risk biomarker for menopausal transition. Future studies should consider a broader population and a more rigorous and thorough study design to validate these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.